More than 75% of Leqembi®-treated patients remained stable and nearly 7% improved over an average of 17 months of treatment in real-world LEADER study data presented at AAIC® 2026

Data ReadoutpositiveLeqembiPositive

AI Analysis

Summary

Real-world LEADER study data presented at AAIC 2026 showed that more than 75% of Leqembi-treated Alzheimer's patients remained stable and nearly 7% improved over an average of 17 months of treatment, supporting the drug's clinical benefit in practice.

Clinical Trial Data

Primary Endpoint

Met

Outcome Details

More than 75% of Leqembi-treated patients remained stable and nearly 7% improved over an average of 17 months of treatment in real-world LEADER study data

Importance:6/10

Sentiment:

0.70

LeqembiAlzheimer's diseasereal-world evidenceLEADER studyAAIC 2026

Related Companies

$BIOA

Read the original article

Published by yahoo_finance on July 14, 2026 3:41 PM

Read Original